Back to top
more

Fate Therapeutics, Inc. (FATE)

(Delayed Data from NSDQ)

$85.73 USD

85.73
561,450

+2.48 (2.98%)

Updated Aug 4, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Fate Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 483 221 201 101 92
Receivables 6 0 1 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 6 6 4 2 1
Total Current Assets 494 227 205 103 93
Net Property & Equipment 32 11 5 3 2
Investments & Advances 0 39 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 29 2 3 0 0
Total Assets 622 302 213 105 95
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 6 6 4 2 1
Current Portion Long-Term Debt 0 0 2 0 8
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 16 15 11 7 4
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 60 6 10 2 2
Total Current Liabilities 86 28 27 11 15
Mortgages 0 0 0 0 0
Deferred Taxes/Income 46 4 8 1 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 12 15 3
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 12 1 5 2 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 238 58 53 28 22
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 941 628 446 296 249
Retained Earnings -557 -384 -285 -219 -176
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 384 245 160 77 73
Total Liabilities & Shareholder's Equity 622 302 213 105 95
Total Common Equity 384 245 160 77 73
Shares Outstanding 87.20 75.50 64.60 50.90 41.30
Book Value Per Share 4.41 3.24 2.48 1.52 1.77

Fiscal Year End for Fate Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Assets          
Cash & Equivalents NA 790 483 489 533
Receivables NA 7 6 3 2
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 7 6 5 5
Total Current Assets NA 804 494 497 540
Net Property & Equipment NA 48 32 21 16
Investments & Advances NA 98 0 13 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 28 29 29 29
Total Assets NA 1,046 622 626 654
Liabilities & Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 6 4 14
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 21 16 15 12
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 60 60 33 18
Total Current Liabilities NA 95 86 54 45
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 43 46 49 55
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 12 15 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 256 238 202 179
Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,392 941 928 919
Retained Earnings NA -602 -557 -504 -445
Other Equity NA -0 0 0 1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 790 384 424 474
Total Liabilities & Shareholder's Equity NA 1,046 622 626 654
Total Common Equity 0 790 384 424 474
Shares Outstanding 94.00 93.80 87.20 86.80 77.60
Book Value Per Share 0.00 8.42 4.41 4.89 6.11